BCR and acute lymphoblastic leukemia: However, no consensus has been reached on the values on these mutations, which may be related to the following three reasons: (1) the relatively small sample sizes; (2) the heterogeneity of the research objects, which included patients with BCR::ABL1‐Positive ALL or a preceding antecedent of CML; and (3) limited by assay no new ABL1 KD mutations detected [37].